Lexaria Bioscience Corp. (LEXX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q3 '16: 6.2K Q1 '17: 9.2K Q2 '17: 12.6K Q2 '17: 12.6K Q3 '17: 29.3K Q1 '18: 24.6K Q2 '18: 172K Q3 '18: 140.3K Q4 '18: 96.4K Q1 '19: 22.2K Q2 '19: 15.3K Q3 '19: 59.9K Q4 '19: 125.1K Q1 '20: 10.3K Q2 '20: 37.5K Q3 '20: 36.4K Q4 '20: 133.7K Q1 '21: 295.7K Q2 '21: 192K Q3 '21: 204.1K Q4 '21: 31K Q1 '22: 13.9K Q2 '22: 30.6K Q3 '22: 99.7K Q4 '22: 111.2K Q1 '23: 97.7K Q2 '23: 20K Q3 '23: 77.7K Q4 '23: 30.7K Q1 '24: 151.3K Q2 '24: 145K Q3 '24: 84K Q4 '24: 84K Q1 '25: 183.9K Q2 '25: 174K Q3 '25: 174K Q4 '25: 174K Q1 '26: 0 Q2 '26: 20K Q3 '26: 0 Q3 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Gross Profit Quarterly

-80K 0 80K 160K 240K Q1 '17: 8.3K Q2 '17: -2.3K Q2 '17: -2.3K Q3 '17: 20.1K Q4 '17: 7.8K Q1 '18: 18.5K Q2 '18: 158.2K Q3 '18: 137.9K Q4 '18: 93.4K Q1 '19: 20.1K Q2 '19: 12.7K Q3 '19: 56.8K Q4 '19: 110.2K Q1 '20: 2.5K Q2 '20: -20.6K Q3 '20: 16.1K Q4 '20: 50.9K Q1 '21: 231.2K Q2 '21: 161.4K Q3 '21: 144.1K Q4 '21: 10.7K Q1 '22: 8.3K Q2 '22: 24.3K Q3 '22: 81.1K Q4 '22: 69.9K Q1 '23: 81.9K Q2 '23: 17.1K Q3 '23: 65K Q4 '23: 30.7K Q1 '24: 146.5K Q2 '24: 145K Q3 '24: 84K Q4 '24: 84K Q1 '25: 181.2K Q2 '25: 174K Q3 '25: 174K Q4 '25: 174K Q1 '26: 0 Q2 '26: 20K Q3 '26: 0 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Operating Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '13: -57.7K Q4 '14: -568K Q1 '15: -398.1K Q2 '15: -458.6K Q3 '15: -511K Q4 '15: -615.6K Q1 '16: -411.7K Q2 '16: -274.6K Q3 '16: -264.2K Q4 '16: -326.7K Q1 '17: -400.6K Q2 '17: -465K Q1 '18: -578.7K Q2 '18: -1.4M Q3 '21: -2.6M Q4 '21: -1.3M Q3 '22: -2.4M Q4 '22: -748.5K Q1 '23: -1.7M Q2 '23: -1.3M Q3 '23: -2.4M Q4 '23: -1.1M Q1 '24: -1.1M Q2 '24: -668K Q3 '24: -1.7M Q4 '24: -2.2M Q1 '25: -2.7M Q2 '25: -2.8M Q3 '25: -3.8M Q4 '25: -2.7M Q1 '26: -1.6M Q2 '26: -1.5M Q3 '26: -2M Q1 '15 Q2 '16 Q1 '18 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Net Income Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '17: -395.4K Q2 '17: -447.8K Q2 '17: -447.8K Q3 '17: -339.1K Q4 '17: -719.8K Q1 '18: -578.7K Q2 '18: -1.4M Q3 '18: -3.4M Q4 '18: -1.2M Q1 '19: -701.4K Q2 '19: -1.2M Q3 '19: -1.2M Q4 '19: -1.1M Q1 '20: -924.8K Q2 '20: -997.5K Q3 '20: -1.4M Q4 '20: -882.4K Q1 '21: -710.1K Q2 '21: 393.2K Q3 '21: -2.6M Q4 '21: -1.2M Q1 '22: -2M Q2 '22: -1.4M Q3 '22: -2.4M Q4 '22: -1.5M Q1 '23: -1.8M Q2 '23: -1.3M Q3 '23: -2.4M Q4 '23: -1.2M Q1 '24: -1.2M Q2 '24: -649.5K Q3 '24: -1.8M Q4 '24: -2.2M Q1 '25: -2.7M Q2 '25: -2.7M Q3 '25: -3.8M Q4 '25: -2.7M Q1 '26: -1.6M Q2 '26: -1.4M Q3 '26: -2M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Cost of Revenue Quarterly

0 30K 60K 90K Q4 '14: 82.1K Q1 '15: 0 Q2 '15: 2.1K Q3 '15: 9.7K Q1 '16: 14.4K Q1 '18: 6.1K Q2 '18: 13.7K Q3 '18: 2.4K Q4 '18: 2.9K Q1 '19: 2.2K Q2 '19: 2.7K Q3 '19: 3.1K Q4 '19: 14.9K Q1 '20: 7.9K Q2 '20: 58.1K Q3 '20: 20.3K Q4 '20: 13.1K Q1 '21: 64.5K Q2 '21: 30.6K Q3 '21: 60K Q4 '21: 20.3K Q1 '22: 5.6K Q2 '22: 6.4K Q3 '22: 18.6K Q4 '22: 41.2K Q1 '23: 15.8K Q2 '23: 3K Q3 '23: 12.7K Q4 '23: 0 Q1 '24: 4.8K Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 2.7K Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q3 '26: 0 Q1 '16 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '16: -260.8K Q1 '17: -101K Q2 '17: -488.1K Q3 '17: -603.5K Q4 '17: -353.3K Q1 '18: -520.3K Q2 '18: -600.9K Q3 '18: -559.7K Q4 '18: -837.1K Q1 '19: -564.3K Q2 '19: -603.3K Q3 '19: -1.1M Q4 '19: -736.6K Q1 '20: -555.1K Q2 '20: -753.9K Q3 '20: -670.5K Q4 '20: -639.3K Q1 '21: -809.5K Q2 '21: -911.2K Q3 '21: -1.2M Q4 '21: -1.1M Q1 '22: -1.2M Q2 '22: -1.3M Q3 '22: -1.3M Q4 '22: -1.2M Q1 '23: -1.2M Q2 '23: -1.2M Q3 '23: -1.8M Q4 '23: -1.6M Q1 '24: -1.2M Q2 '24: -619.6K Q3 '24: -1.3M Q4 '24: -1.9M Q1 '25: -2.7M Q2 '25: -1.5M Q3 '25: -3.6M Q4 '25: -2.6M Q1 '26: -984.1K Q2 '26: -2.2M Q3 '26: -1.6M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Free Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q1 '15: -173.2K Q4 '15: -580.9K Q1 '16: -212K Q4 '16: -260.8K Q1 '17: -101K Q4 '17: -353.3K Q1 '19: -687.1K Q2 '19: -921.6K Q3 '19: -1.3M Q4 '19: -746.1K Q1 '20: -555.1K Q4 '20: -639.3K Q1 '21: -809.5K Q1 '22: -1.2M Q2 '22: -1.3M Q3 '22: -1.3M Q4 '22: -1.2M Q1 '23: -1.3M Q2 '23: -1.2M Q3 '23: -1.8M Q4 '23: -1.6M Q1 '24: -1.2M Q2 '24: -619.6K Q3 '24: -1.3M Q4 '24: -1.9M Q1 '25: -2.8M Q2 '25: -1.5M Q3 '25: -3.6M Q4 '25: -2.6M Q1 '26: -984.1K Q2 '26: -2.2M Q3 '26: -1.6M Q4 '16 Q2 '19 Q4 '20 Q3 '22 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q4 '10: 12.7M Q2 '11: 13M Q3 '11: 13.1M Q4 '11: 14.3M Q2 '12: 16.4M Q3 '12: 16.4M Q4 '12: 16.4M Q1 '24: 9.1M Q2 '24: 10.8M Q3 '24: 13.9M Q1 '25: 16.7M Q2 '25: 17.5M Q3 '25: 18.3M Q1 '26: 21.4M Q2 '26: 24.4M Q3 '26: 24.8M Q2 '11 Q4 '11 Q3 '12 Q1 '24 Q3 '24 Q2 '25 Q1 '26 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '11: -0.04 Q1 '12: -0.04 Q2 '12: -0.04 Q3 '12: -0.04 Q4 '12: -0.02 Q1 '13: -0.02 Q2 '13: -0.02 Q3 '13: -0.01 Q4 '13: -0.01 Q1 '16: -0.04 Q2 '16: -0.04 Q3 '16: -0.04 Q4 '16: -0.04 Q1 '17: -0.04 Q1 '18: -0.04 Q2 '18: -0.05 Q3 '18: -0.09 Q4 '18: -0.09 Q1 '19: -0.09 Q2 '19: -0.08 Q3 '19: -0.04 Q4 '19: -0.04 Q1 '20: -0.36 Q2 '20: -0.73 Q3 '20: -1.22 Q4 '20: -1.45 Q1 '21: -1.36 Q2 '21: -0.89 Q3 '21: -0.89 Q4 '21: -0.89 Q1 '22: -1.00 Q2 '22: -1.34 Q4 '24: -0.47 Q1 '25: -0.50 Q2 '25: -0.59 Q3 '25: -0.67 Q4 '25: -0.65 Q1 '26: -0.56 Q2 '26: -0.47 Q3 '26: -0.34 Q4 '12 Q1 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q2 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.